Survey of the diagnostic value of leishmania in skin lesions in patients through direct smear and culture media

Schizophrenia has a prevalence of 1% and accounts for 2.5% of heath-care in USA. FDA has approved the drug Clozapine for treatment of drug resistant forms of schizophrenia. The aim of this study was the comparative therapeutic’s effect of clozapine and risperidone in the drug resistant schizophrenia. In this cross-sectional study therapeutic effect of two different drugs clozapine and rispridone have been compared on 40 drug resistant male and female schizophrenia cases admitted in Rehabilitation Center of Chronic Mental Diseases of Zahedan Welfare Organization in Iran. Patients were divided in two groups for treatment with either clozapine or rispridone. The patient’s improvement was evaluated with clinical interviews and BPRS tests. The data was analyzed by Chi-Square and t-test variance analysis. Initial BPRS results was determined as an average of 52.80±7.70 for clozapine group and average of 49.80±5.98 for rispridone group. Three month after start of treatment average of BPRS and SD was 22.95, 1.57, 24.53 for clozapine group, and 2.49 for rispridone group respectively. The average decrease in BPRS was calculated as 29.58±7.08 for clozapine and 25.49±5.94 for rispridone. The statistical markers were determined as P= 0.48 and t-test =-2.13. The results confirm that clozapine acted more effectively than rispridone and has been tolerated by the patients.